| Name | Title | Contact Details |
|---|
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
genetic Immunity is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
STERIS Instrument Management Services is a surgical device and instrument management and consulting company.
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.
Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.